{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.8","upperLimit":"25.5","value":"15.1"},{"comment":"Upper limit of Confidence Interval (CI) was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"3.5","upperLimit":"NA","value":"18.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Duration of response was assessed by the IRF in participants with confirmed response \\[CR or Partial Response (PR)\\] and is defined as the time between first documentation of response and disease progression. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"OG001","title":"Methotrexate or Bexarotene"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment. Responders in ITT population were analyzed in this outcome measure.","reportingStatus":"POSTED","timeFrame":"Until disease progression, death or data cutoff (Median follow-up 38.8 months)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}